Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

portfolio company news
Written By Megan Prock McGrath

Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS), and provided an update on the Company's pipeline and prioritization.

Megan Prock McGrath
Previous

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Next

Trice Medical Launches Tenex® 2nd Generation Ultrasonic System, Expanding Minimally Invasive Treatment For Chronic Tendon Paid